tiprankstipranks
Trending News
More News >

Onconetix to Present Proclarix at EAU Congress 2025

Story Highlights
  • Onconetix’s abstract on Proclarix was accepted for presentation at the 2025 EAU congress.
  • Proclarix reduces unnecessary biopsies by ruling out insignificant prostate cancer.
  • Looking for the best stocks to buy? Follow the recommendations of top-performing analysts.
Onconetix to Present Proclarix at EAU Congress 2025

The latest update is out from Onconetix ( (ONCO) ).

On March 19, 2025, Onconetix announced that its abstract on the clinical performance of Proclarix, a prostate cancer diagnostic test, was accepted for presentation at the 2025 European Association of Urology congress in Madrid. The presentation will highlight Proclarix’s ability to reduce unnecessary biopsies by effectively ruling out clinically insignificant prostate cancer, demonstrating its potential impact on improving prostate cancer diagnosis and treatment.

More about Onconetix

Onconetix, Inc. is a commercial stage biotechnology company focused on men’s health and oncology. The company specializes in the research, development, and commercialization of innovative solutions, including Proclarix, an in vitro diagnostic test for prostate cancer, and ENTADFI, a treatment for benign prostatic hyperplasia.

YTD Price Performance: -80.92%

Average Trading Volume: 10,166,483

Technical Sentiment Consensus Rating: Buy

Current Market Cap: $1.81M

Find detailed analytics on ONCO stock on TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App